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STAT3 serine phosphorylation is required for TLR4
metabolic reprogramming and IL-1β expression
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Detection of microbial components such as lipopolysaccharide (LPS) by Toll-like receptor 4
(TLR4) on macrophages induces a robust pro-inflammatory response that is dependent on
metabolic reprogramming. These innate metabolic changes have been compared to aerobic
glycolysis in tumour cells. However, the mechanisms by which TLR4 activation leads to
mitochondrial and glycolytic reprogramming are unknown. Here we show that TLR4 acti-
vation induces a signalling cascade recruiting TRAF6 and TBK-1, while TBK-1 phosphorylates
STAT3 on S727. Using a genetically engineered mouse model incapable of undergoing STAT3
Ser727 phosphorylation, we show ex vivo and in vivo that STAT3 Ser727 phosphorylation is
critical for LPS-induced glycolytic reprogramming, production of the central immune response
metabolite succinate and inflammatory cytokine production in a model of LPS-induced
inflammation. Our study identifies non-canonical STAT3 activation as the crucial signalling
intermediary for TLR4-induced glycolysis, macrophage metabolic reprogramming and
inflammation.
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TLR4 activation induces metabolic changes in macrophagesvia mitochondrial reprogramming, which is required tomeet the rapid increase in demand for biosynthetic pre-
cursors for lipids, proteins, nucleic acids and the increased energy
demand of the inflammatory state1–4. LPS-induced transcription
of inflammatory cytokines and chemokines is also dependent on
metabolic reprogramming2,5.
Activated macrophages become more glycolytic, increase
reactive oxygen species (ROS) production, and accumulate the
tricarboxylic acid (TCA) cycle metabolite succinate redirecting it
away from oxidative phosphorylation via the electron transfer
chain (ETC). Recent studies have identified that the TLR down-
stream kinases TBK-1 and IKKε play a role in inducing glycolysis
in immune cells6,7 via phosphorylation of Akt6, although how
these signals converge on, and orchestrate mitochondrial meta-
bolic function remain unclear.
Metabolic signalling in response to elevated succinate con-
centration leads to the stabilisation of hypoxia inducible factor-1α
(HIF-1α), which positively regulates the prototypic inflammatory
cytokine IL-1β and other HIF-1α-dependent genes involved in
glycolysis8. However, the molecular mechanisms of how
membrane-bound TLRs communicate this signal to the mito-
chondria to alter mitochondrial function are also unclear.
STAT3 is a critical signalling molecule activated by immune
cytokines resulting in phosphorylation on Tyr705 and activation
of its activity as a transcription factor9. In addition to this
essential activity in the nucleus we, and others, have shown that a
pool of Ser727 phosphorylated STAT3 translocates into the
mitochondria where it affects mitochondrial metabolism and
ROS generation10,11,12.
In this study we interrogate the activation of STAT3 by TLRs
as a mechanism to directly alter mitochondrial metabolism.
STAT3 interacts directly with TLR signalling pathways via
interaction with TRAF6 and TBK-1, resulting in non-canonical
STAT3 Ser727 phosphorylation. STAT3 pSer727 is subsequently
required for TLR-induced mitochondrial reprogramming and
production of inflammatory cytokines. These studies identify a
function for STAT3 in TLR-induced metabolic reprogramming
and inflammation.
Results and discussion
TRAF6 interacts with STAT3 following TLR4 challenge. Acti-
vation of TLRs, with the exception of TLR3, sequester MyD88 to
the receptor complex, initiating recruitment of the serine kinases
IRAK1 and IRAK4 into the Myddosome complex7,13–16. This
complex subsequently interacts with TRAF6 to activate the
canonical signalling pathway, resulting in the nuclear transloca-
tion of NF-κB and induction of the classic pro-inflammatory
response17. Alternatively, TLR3 and TLR4 also engage the
adaptor TRIF leading to the activation of the serine kinase TBK-1
and subsequent phosphorylation of IRF3 leading to nuclear
translocation and induction of IFNβ expression.
TRAF6 represents a major point of bifurcation of TLR
signalling between canonical and non-canonical induction of
inflammation. Structural analysis of TRAF6-binding partners
show a conserved binding motif consisting of Pro-X-Glu-X-X-
(aromatic or acidic residue)18, required for interaction with
downstream signalling proteins including Mal/TIRAP, TRIF,
TRAM and STAT119–22. Given the homology between STAT
proteins and the role for STAT3 in mitochondrial reprogram-
ming, we identified highly conserved putative TRAF6-binding
motifs within STAT3 (Fig. 1a) and confirmed that the interaction
between endogenous TRAF6 and STAT3 occurs within 10 min of
LPS-stimulation in macrophages (Fig. 1b). To ascertain the
importance of the putative TRAF6 binding sites in STAT3 we
generated a series of mutant STAT3 constructs, which were
transiently expressed in 293T cells and bound to recombinant
GST-tagged TRAF6 ex vivo. This data revealed selectivity for
Glu100, i.e. STAT3 E100A completely abolished the interaction
with TRAF6, which was not observed for the other putative
interaction motifs (Fig. 1c).
TLRs induce STAT3 Ser, by not Tyr, phosphorylation. Initially,
we treated immortalised bone marrow-derived macrophages
(iBMDMs) with IFNα as a well-known activator of STAT3. While
we observed background Ser727 phosphorylated STAT3 in
untreated cells, iBMDMs exhibit rapid increases in phosphor-
ylation on both Ser727 and Tyr705 (Fig. 2a) as expected. In
contrast TLR ligands are reported to initiate phosphorylation of
STAT3 on Tyr705 only after prolonged stimulation more con-
sistent with secondary and indirect activation. To resolve whether
TLR activation induced rapid STAT3 phosphorylation, we chal-
lenged primary bone marrow-derived macrophages (BMDMs)
with LPS and observed S727 phosphorylation within 20 min of
challenge, whereas Tyr705 phosphorylation was not detected even
after 120 min (Fig. 2b). To establish whether STAT3 Ser727
phosphorylation was induced by all TLRs we stimulated macro-
phages with Pam3Cys (TLR2), poly I:C (TLR3), Loxoribine
(TLR7), CpG-DNA (TLR9) or IFNα as a positive control. All TLR
agonists induced Ser727, but not Tyr705 phosphorylation of
STAT3, whilst IFNα induced both pSer727 and pTyr705 as
expected (Fig. 1c).
Stimulation of the TLR signalling pathway has at least two
phases of response. The early response which is dependent upon
the Myddosome complex components MyD88 and TRIF, leading
to the activation of NF-κB and Interferon regulatory factor (IRF)-
3 which drive the transcription of a suite of inflammatory genes
including type I IFN17; and the secondary response to secreted
type I IFN. To confirm that STAT3 Ser727 phosphorylation is
due to TLR activation directly and not as a consequence of
autocrine cytokine or type I IFN signalling, we established the
phosphorylation of STAT3 on S727 in cells lacking the critical
Myddosome factor MyD88 and TRIF or lacking the type I IFN
receptor (IFNAR1). We show that LPS does not induce STAT3
phosphorylation on S727 in MyD88−/−/TRIF−/− iBMDMs
(Fig. 1d) but is unaffected in IFNAR1−/−-deficient macrophages
(Fig. 1e). Taken together these results demonstrate, for the first
time, that STAT3 is directly recruited into the TLR signalling
pathway via interaction with TRAF6, resulting in STAT3 Ser727,
but not Tyr705 phosphorylation.
TLR-induced Ser727 phosphorylation of STAT3, in the
absence of Tyr705 phosphorylation is consistent with the
activation of the novel mitochondrial STAT3 activity that we
have previously described in RAS transformed cancer cells11.
While the majority of STAT3 is present in the cytosol, a pool of
STAT3 translocates into the mitochondria, causing metabolic
reprogramming, and altering ROS production, dependent on
pSer727 but independent of Tyr705 phosphorylation11. We
therefore, performed biochemical fractionation of LPS-treated
macrophages (Fig. 1f) and demonstrate an enrichment of STAT3
pSer727 in mitochondrial fractions after 60 min LPS stimulation.
Taken together, these results demonstrate that STAT3 undergoes
rapid TLR-induced Ser727, but not Tyr705 phosphorylation and
an accumulation in the mitochondrial fraction of macrophages.
TBK-1 is required for TLR4-mediated STAT pSer727. We next
wished to identify the potential kinase responsible for TLR-
induced STAT3 Ser727 phosphorylation. We have previously
shown that the mitochondrial activity of STAT3 results in
increased mitochondrial ROS (mtROS) production23. Therefore,
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to identify potential kinases responsible for LPS-induced STAT3
Ser727 phosphorylation we used mtROS concentration as a
functional readout of activity and screened a library of 355 kinase
inhibitors (Supplementary Dataset 1). Macrophages were pre-
treated with inhibitors for 30 min prior to LPS challenge and
mtROS production monitored every hour for 4 h (Supplementary
Fig. S1) using the mitochondrial superoxide probe MitoSOX. As a
positive control we included the ROS scavenger N-Acetyl-L-
cysteine in all screens. This screening approach identified several
classes of inhibitors capable of reducing LPS-induced mtROS
production (Fig. 2a); including PI3K, mTOR and Inhibitor of IκB
kinase (IKK) inhibitors. Interestingly, we also identified an inhi-
bitor of tank binding kinase-1 (TBK-1) as a suppressor of LPS-
induced mtROS production. Importantly, IRAK1 and IRAK4 are
serine kinases that interact with TRAF618 and the MyDDosome
whose kinase activity is critical for TLR-signalling and NF-κB
activation13. We found however, that a specific inhibitor of
IRAK-1/4 activity had no effect on LPS-induced mtROS pro-
duction, and therefore may not be responsible for STAT3 phos-
phorylation, acting as a specificity control for this screen.
This is consistent with the recent publication from Tan and
Kagan7 who showed that TRAF6 depleted macrophages are
defective for TBK-1 recruitment to the Myddosome and
induction of TLR glycolysis. Analysis of the TBK-1 sequence
revealed a putative TRAF6 binding motif (human amino acids
223–228) suggesting the potential interaction between these
proteins. Indeed, immunoprecipitation of endogenous protein
show that TBK-1 directly interacts with TRAF6 following LPS
stimulation in a time-dependent and transient manner (Fig. 2b).
This TBK-1-TRAF6 interaction was observed within 10 min of
LPS stimulation and was no longer detectable after 120 min post-
stimulation. Our previous data demonstrate interaction between
TRAF6 and STAT3 and led us to propose the formation of a
TBK-1, TRAF6, STAT3 complex to enable TBK-1 phosphoryla-
tion of STAT3 in response to LPS challenge. Consistent with this
we show that STAT3 interacted with phosphorylated TBK-1, with
kinetics that are slightly offset from that of the TRAF6-TBK-1
interaction (Fig. 2c). Importantly, the immunoprecipitated
STAT3 was phosphorylated on Ser727.
Whilst interaction studies and our mtROS inhibitor screen
suggest that TBK-1 is the kinase upstream of STAT3 S727
phosphorylation in response to LPS stimulation we wanted to
formally test this. We therefore examined STAT3 S727
phosphorylation in TBK-1-deficient macrophages. As can be
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Fig. 1 STAT3 directly interacts with TRAF6 after LPS stimulation. a Schematic representation of the putative TRAF6-binding domains and
phosphorylation sites of STAT3. ND: N-terminal domain: SH2: Src homology domain TAD: transactivation domain. b BMDMs (1 × 107 cells) were
seeded in 10 cm culture dishes and grown for 24 h prior to stimulation with LPS (1 μg/ml) for indicated times. TRAF6 was immunoprecipitated from cellular
lysates and probed with anti-TRAF6, or STAT3 antibody (n= 3) c HEK293T cells (1 × 106) were transfected with indicated plasmid vectors for 24 h. Cells
were lysed and probed with recombinant GST-TRAF6 to immunoprecipitated interacting proteins, separated by SDS-PAGE and probed with anti-FLAG
antibody (n= 3).
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seen in Fig. 3d, we observed a consistent reduction in STAT3
S727 phosphorylation of ~50% when compared with WT cells,
suggesting that TBK-1 is involved in STAT3 Ser727 phosphor-
ylation. Previous studies have shown that TBK-1 and its closely
related kinase IKKε are involved in TLR-induced glycolytic
reprogramming6 and that deletion of TBK-1 in IKKε−/−
macrophages reduced LPS-induced glycolysis that was dependent
upon TRAF6 interaction suggesting that IKKε may play a role
also in STAT3 phosphorylation.
We therefore pre-treated macrophages with the inhibitor BX-
795, at 1 μM, at which concentration it is known to target both
TBK-1 and IKKε24,25, for 30 min prior to LPS stimulation. This
pre-treatment reduced STAT3 Ser727 phosphorylation to back-
ground levels (Fig. 2e). These data suggest that the closely related
kinases TBK-1 and IKKε are involved in STAT3 Ser727
phosphorylation. These findings are consistent with previous
studies identifying interaction between overexpressed TRAF6 and
TBK-1, and that these kinases may also play a role in downstream
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TLR signalling independent of their established role in mediating
TLR-induced IRF3 phosphorylation and induction of IFNβ26.
While PI3 kinase and Akt have previously been implicated in
TLR-induced glycolytic reprogramming via TBK-1/IKKε6, none of
the seven Akt inhibitors screened in our study reduced LPS-
induced mtROS (Fig. 3a). We therefore examined whether the PI3
kinase inhibitor TG100713 could also inhibit LPS-induced STAT3
Ser727 phosphorylation and noted that this inhibitor had no effect
upon LPS-induced phosphorylation (Supplementary Fig. S2).
Therefore, while Akt has previously been identified as a down-
stream target of TBK-1/IKKε in TLR-induced glycolysis in
dendritic cells6, neither Akt nor PI3 kinase were implicated in
TBK-1-mediated glycolysis in macrophages7 and do not appear
to play a role in STAT3 S727 phosphorylation in macrophages.
Together however, these studies identify a TRAF6, TBK-1/
STAT3 signalling nexus leading to STAT3 S727 phosphorylation
and mitochondrial localisation, providing a potential mechanism
for the previously described role of TBK-1/IKKε signalling in
TLR-induced glycolysis6,7.
Indeed, while non-canonical TBK-1 recruitment and phos-
phorylation was identified as critical in macrophage LPS-induced
glycolysis7, the role of Akt in macrophage signalling was not
established akin to dendritic cells6. Moreover, the role of these
kinases may reflect cell specific signalling differences between
macrophages and dendritic cells or reflect the kinetics of early
and late glycolytic metabolic reprogramming pathways.
While the induction of glycolysis and metabolic reprogram-
ming is increasingly recognised for its importance in the
inflammatory state in macrophages, the mechanism of how TLRs
promote this response is unknown. Our discovery identifies a
molecular function for non-canonical kinase activity in TLR
signalling via TBK-1 phosphorylation of STAT3, which subse-
quently translocates to the mitochondria.
STAT3 pSer727 required for TLR-induced metabolic repro-
gramming. Given that TBK-1 has been previously demonstrated
to promote TLR-dependent glycolysis and that we have reported
STAT3 Ser727-dependent metabolic changes, we hypothesised
that the loss of STAT3 Ser727 phosphorylation would impede
metabolic reprogramming. To address this, we performed a panel
of metabolic analysis on primary peritoneal macrophages
obtained from mice in which a serine to alanine (S727A) muta-
tion was knocked into the endogenous STAT3 locus27 abolishing
Ser727 phosphorylation (STAT3 S727A; herein termed STAT3
SA). We used peritoneal exudate cells (PECs) for these studies
because of the known requirement for STAT3 in growth factor
signalling and differentiation (e.g. CSF-1, GM-CSF pathways)28,
moreover, PECs represent the local immunological environment,
consisting predominately of myeloid cells29. We found that
STAT3 SA PECs have a significant defect in both resting glyco-
lysis and the early glycolytic burst observed in wild-type macro-
phages following LPS-challenge by assaying the ECAR (Fig. 4a).
Together with the previous observations in TBK-1/IKKε-deficient
cells7, these data support the concept that phosphorylation of
STAT3 induces metabolic reprogramming.
To establish whether STAT3 Ser727 phosphorylation is
necessary for mitochondrial reprogramming, we exposed WT
and STAT3 SA peritoneal macrophages to LPS for 24 h and
observed ablation of the ECAR and mitochondrial oxygen
consumption rate (OCR) in STAT3 SA compared with
WT cells (Fig. 4b, c). We next examined the functional capacity
of the electron transport chain by determining the changes in
OCR following sequential treatment of cells with mitochondrial
ETC inhibitors. These data suggest that S727 phosphorylation of
STAT3 is critical to elicit LPS-induced mitochondrial reprogram-
ming and suggests STAT3 has parallel roles in LPS-induced
metabolic reprogramming to that observed in tumour cells.
Consistent with what we have previously observed in cancer
cells11, the loss of STAT3 S727 phosphorylation leads to a
diminished basal respiration rate. Moreover, STAT3 SA macro-
phages had a significant reduction in their maximal respiratory
capacity compared with WT cells (Fig. 4d, e). These data mean
whilst STAT3 SA PECs are viable and actively respiring, they are
operating at close to their maximal capacity even in the absence
of LPS stimulation. It should also be noted that the increase in
basal respiration following a 24 h LPS-treatment of peritoneal
macrophages we observe is the opposite of the LPS-mediated
suppression of OCR observed in BMDMs, but is consistent with
other studies on PECs30,31. This potentially reflects the different
polarisation of these macrophage populations, where PECs
display higher expression of M1 markers when compared with
BMDMs32. Indeed, in addition to the intrinsic metabolic
differences in macrophages from diverse microenvironments, it
has been suggested that the process of culturing BMDMs for
7 days in M-CSF culturing may bias them towards M2
differentiation as compared with peritoneal macrophages33.
Therefore, while both cell types are display an intrinsic capacity
to induce a potent inflammatory response to challenge, their
metabolic responses differ.
Macrophage activation by LPS is accompanied by a remodel-
ling of the TCA cycle resulting in accumulating concentrations of
TCA metabolites including succinate, which plays a critical role in
mitochondrial reprogramming and inflammatory cytokine pro-
duction. We found that WT peritoneal macrophages treated with
LPS for 24 h displayed significantly increased succinate as
expected. However, STAT3 SA macrophages failed to increase
succinate concentrations as observed with wild type (WT)
macrophages (Fig. 4f). Our data also show that STAT3 SA
macrophages have lower basal ECAR, which is increased in
response to LPS but not to the magnitude observed in WT
macrophages. This is in line with previous observations that
mitochondria from STAT3 SA cells are defective in ETC
activity10,11. Thus, STAT3 SA mitochondria may be more reliant
on aerobic glycolysis that is consistent with the significant
increase in the lactate concentration in STAT3 SA macrophages
in response to LPS stimulation (Fig. 4g). However, the lactate
Fig. 2 TLR stimulation induces STAT3 pSer and mitochondrial localisation. a Immortalised BMDMs (iBMDMs) (1 × 106) were treated with IFNα (1000
U) for indicated times, b BMDMs (1 × 106 cells/well) were treated with LPS for indicated times, and c BMDMs were also treated with TLR agonists,
Pam3Cys (TLR2, 100 ng/ml), Poly I:C (TLR3, 500 ng/ml), LPS (TLR4, 100 ng/ml), Loxoribine (TLR7, 10mM), CpG-DNA (TLR9, 2.5 μM) and IFNα (IFNAR1,
1000 U) for 60min. STAT3 phosphorylation status was detected by immunoblot of cellular lysates with anti-STAT3, anti-STAT3 pS727 and anti-STAT3
pY705 antibodies as indicated (n= 3). d MyD88−/−/TRIF−/− iBMDM or e IFNAR1−/− BMDMs were treated with TLR ligands (n= 2) as described and
immunoblot analysis with anti-STAT3 pS727 and anti-STAT3 antibodies of cellular lysates show ablated TLR-induced STAT3 Ser727 phosphorylation
compared with IFNAR1-deficient BMDMs (Fig. 3e), but not IFNα (n= 2). (F) iBMDMs were treated with PBS or LPS (100 ng/mL) for 1 h and whole cell
lysate, S100 or clean mitochondrial fractions isolated and separated by SDS-PAGE. Abundance of STAT3 and pS727 STAT3 in each fraction was observed
as was fraction purity by probing with antibodies against Erk2 (S100), VDAC (mitochondria) or Lamin A/C (nucleus). Data shown are the mean ± S.E.M of
a n= 1, b n= 5, c, e n= 3, d, f n= 2 independent experiments.
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concentration in LPS-treated STAT3 SA macrophages only ever
approaches the lactate concentration observed in unchallenged
WT macrophages. In addition, we do not observe any increase in
the lactate concentration in WT macrophages in response to LPS
stimulation. Given that ECAR is typically associated with lactate
production, this result appears somewhat counter-intuitive.
However, it is important to note that ECAR also measures the
export of CO2, hydration of H2CO3 and the dissociation to HCO3
and H+ from the respiratory chain which also contributes to the
ECAR reading34. Together, these data show that LPS induced
STAT3 Ser727 phosphorylation is required for TCA cycle
(succinate concentration) and OXPHOS (OCR) augmentation.
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IL-1β production after TLR4 challenge is STAT3 dependent.
Previous studies have emphasised that enhanced succinate pro-
duction is a critical regulator of the pro-inflammatory response
via ETC-mediated mtROS production, the expression of IL-
1β2,8,35. Consistent with these observations we show that STAT3
SA macrophages generate significantly less IL-1β mRNA
expression (Fig. 5a). We therefore, examined the kinetics and
expression of cytokines in STAT3 SA PECs following LPS sti-
mulation. Consistent with our mRNA data, while IL-1β expres-
sion increased steadily between 4 and 24 h of LPS challenge, IL-1β
protein expression was significantly suppressed in STAT3 SA cell
lysates compared with WT cells (Fig. 5b). Furthermore, TNF
expression was reduced in STAT3 SA compared with WT cells
(Fig. 5c), but did continue to increase parallel to WT expression,
while IL-6 concentrations were only significantly different at 24 h
post-LPS (Fig. 5d). Interestingly, whilst we observed increased IL-
10 expression in unstimulated STAT3 SA macrophages, they did
not respond to LPS with the increase in IL-10 production
observed in WT cells (Fig. 5e). These results demonstrate that
STAT3 Ser727 plays a crucial role in inflammatory cytokine
expression following LPS challenge. Importantly, these findings
are consistent with previous studies characterising metabolic
reprogramming as integral to IL-1β production2,8,35, while the
temporal increase in cytokines such as IL-6 may be due to
reduced autocrine induction due to reduced IL-1β or TNF pro-
duction. Interestingly it also suggests that STAT3 Ser727 phos-
phorylation may play a role in steady state IL-10 expression.
Increased aerobic glycolysis in macrophages plays a critical role
in disease pathogenesis during endotoxemia8. To investigate the
role of STAT3 Ser727 phosphorylation in TLR-induced inflam-
mation in vivo, we examined STAT3 SA mice in a model of LPS-
induced sepsis. As can be seen in Fig. 5f-i, STAT3 SA mice
demonstrate significantly reduced IL-1β, IL-6 and Ccl2, but not
TNF, production in serum following acute LPS challenge,
compared with WT mice. Consistent with our in vitro studies
we observed no difference in IL-10 expression (Fig. 5j) which
reflect the early response to LPS stimulation, whereas IL-10
expression may be delayed. Taken together, these results highlight
the specificity of Ser727 phosphorylated STAT3 in mediating
inflammatory gene induction.
Increasing evidence positions metabolic reprogramming as a
key event in the inflammatory response following TLR
activation. Importantly, this study identifies, for the first time,
the molecular mechanism by which TLR signalling commu-
nicates with the mitochondria. We have demonstrated that
TBK-1 contains a putative TRAF6 binding site allowing its
direct recruitment to the TLR signalling pathway, facilitating
TBK-1-mediated STAT3 Ser727 phosphorylation and translo-
cation to the mitochondria. Macrophages unable to undergo
STAT3 Ser727 phosphorylation display impaired TLR-induced
glycolytic reprogramming, reduced pro-inflammatory metabo-
lite production and diminished inflammation. This discovery
parallels observations made in cancer cells, which further
enhances the concept that inflammatory macrophages induce
the Warburg effect to engender a pro-inflammatory phenotype.
As such, STAT3 is not only a central immune regulatory
transcription factor, but additionally rapidly orchestrates innate
immune mitochondrial reprogramming and inflammatory cell
metabolism via non-canonical signalling.
Methods
BMDM cell culture. WT, IFNAR1−/− (kind gift from Prof Paul Hertzog, Hudson
Institute of Medical Research), TBK-1 F/F, TBK-1 F/F/Vav-iCre BMDMs were
differentiated in DMEM containing 30% M-CSF conditioned media obtained from
supernatants of L929 fibroblasts, centrifuged to remove cell debris (5 min, 300 g)
and filtered through a 0.22 μm filter. Leg bones of mice were surgically removed
and cleaned bones were cut with scissors and flushed with sterile PBS via a syringe.
Bone marrow suspension was passed through a 70 μm cell strainer to remove
clumps and cells cultured in low-adherence 10 cm tissue culture plates in
L929 supplemented 10% FCS, DMEM (Gibco) with added L-glutamine (Gibco) at
37 °C, 5% CO2 for 7 days. Cells were supplemented with a further 5 ml of L929
conditioned FCS/DMEM on day 3. Cells were removed from tissue culture plates
with gentle scrapping and seeded at desired densities in 1% FCS/DMEM, supple-
mented with L-glutamine 24 h prior to stimulation or treatment.
Immortalised WT and MyD88−/− TRIF−/− BMDMs (iBMDMs) were
generated from indicated mice with J2 recombinant retrovirus carrying v-myc and
v-raf oncogenes36,37.
Immortalised WT BMDMs were a kind gift of Prof Douglas Golenbock
(UMASS). HEK293T cells were obtained from ATCC were grown in 10% FCS
in DMEM supplemented with L-glutamine and grown in humidified 5% CO2
at 37 °C.
Mice. All experimental procedures were approved by the Monash Medical Centre
Animal Ethics Committee. 6–12 weeks of age female and male mice were used.
STAT3 S727A (STAT3 SA)27, IFNAR1−/− and C57BL/6J WT were maintained at
the Monash Medical Centre Animal Facility under specific pathogen-free condi-
tions in accordance with Australian Government animal welfare regulations. TBK-
1 F/F and TBK-1 F/F/Vav-iCre were maintained at the UMass Medical School
Animal Facility in compliance with the federal regulations set forth in the Animal
Welfare Act, the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health, and the guidelines of the
UMass Medical School Institutional Animal Use and Care Committee.
Peritoneal macrophage isolation. Peritoneal cells were collected from WT and
STAT3 S727A (STAT3 SA) mice via peritoneal lavage with 5 ml of cold sterile PBS
supplemented with 5 mM EDTA. Cells were centrifuged (300 g, 5 min) and allowed
to adhere to tissue culture plates for 1 h in 10% FCS, DMEM (Gibco) and 2 mM L-
glutamine (Gibco). Cells were washed three times with sterile PBS after 180 min to
remove non-adherent cells and grown overnight at 37 °C, 5% CO2 in 1% FCS/
DMEM supplemented with 2 mM L-glutamine prior to experimentation29.
Immunoprecipitation of TRAF6 and STAT3. To identify the binding interface
between STAT3 and TRAF6 we generated a panel of STAT3 mutants by site
directed mutagenesis of E28, E100, E680 or E28 and E680 using the following
primers E28A: F 5′- CAGTGACAGCTTCCCATGGCGCTGCGGCAGTTTC; R
5′- GAAACTGCCGCAGCGCCATGGGAAGCTGTCACTG, E100A: F 5′- CTTGA
GAAGCCAATGGCGATTGCCCGGATTGTG; R 5′- CACAATCCGGGCAATCG
CCATTGGCTTCTCAAG, E680A: F 5′-CACAATCCGGGCAATCGCCATTGGC
TTCTCAAG, R 5′- CTTGAGAAGCCAATGGCGATTGCCCGGATTGTG. The
resultant FLAG-tagged STAT3 constructs were transfected into 293T using lipo-
fectamine 3000 (Thermo Fisher Scientific, Cat# L3000001). 48 h after transfection
cells were lysed (50 mM Tris, pH 7.4, 1.0% Triton X-100, 150 mM NaCl, 1 mM
EDTA, 2 mM Na3VO4, 10 mM NaF, 1 mM PMSF and protease cocktail inhibitor
(Roche)) and centrifuged at 18,000 g for 5 min (4 °C) to remove debris. GST tagged
TRAF6 C-domain was cloned into pGEX-4T-3 and expressed in BL21(DE3)
Fig. 3 TBK-1 interacts with and functions in STAT3 Ser727 phosphorylation. a iBMDMs were seeded at 4 × 104 cells per well in triplicate 24 h prior to
pretreatment with kinase inhibitors (Y-axis; 500 nM) for 30min. MitoSOX was added for 10 min prior to challenge with LPS (100 ng/ml; 0, 1, 2 and 4 h).
LPS-induced production of superoxide by mitochondria was analysed by measuring oxidised MitoSOX fluorescence at 580 nm. See also Supplementary
Fig. 1. Cell lysates from LPS stimulated BMDMs (0–120min) were immunoprecipitated with b anti-TRAF6 and c anti-STAT3 antibodies. TBK-1 interaction
with TRAF6 and STAT3 was identified by immunoblot with anti-TBK-1 and anti-TBK-1 pS172 antibodies respectively. b, c Data represents three independent
experiments with similar results. d TBK-1-deficient and WT macrophages were treated with LPS or IFNα for indicated times and STAT3 phosphorylation
assayed in cellular lysates by immunoblot with indicated antibodies. TBK-1 expression was ascertained by immunoblot with anti-TBK-1 antibody. e BMDMs
were pretreated with the TBK-1/IKKε (1 μM) inhibitor BX-795 for 60min prior to LPS stimulation for indicated times. STAT3 and TBK-1 phosphorylation
was observed by immunoblot with indicated antibodies. DMSO was added to lanes 13–14 as vehicle control. Immunoblot results are representative of three
independent experiments and data presented (d, e) as mean ± S.E.M.
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Fig. 4 STAT3 pSer727 is required for LPS-induced metabolic reprogramming. a Peritoneal macrophages (1 × 105/well) obtained from WT vs STAT3 SA
mice (n= 3 per genotype). Real-time changes in the extracellular acidification rate (ECAR) of WT and STAT3 SA macrophages treated with LPS (b, c) WT
and STAT3 SA peritoneal macrophages were stimulated with LPS or vehicle as indicated for 24 h. b ***p < 0.0001, and c **p= 0.0034, ***p < 0.0001.
a, b The ECAR and oxygen consumption rate (OCR) were analysed as indicators of oxidative phosphorylation and glycolysis, using a Seahorse XFp
analyser. d Peritoneal macrophages were assayed for real-time changes in the OCR by sequential treatment with sequential treatment of cells with electron
train chain inhibitors (oligomycin: adenosine triphosphate (ATP) synthase inhibitor; FCCP: H+ ionophore cyanide p-triflurmethooxyphenyl-hydrozone; and
Complex I inhibitor rotenone). e Comparison of maximal respiratory capacity (MRC) between WT and STAT3 SA peritoneal macrophages stimulated
with LPS or vehicle for 24 h. Results presented (a–e) as the mean ± S.E.M of peritoneal macrophages obtained from three individual mice per genotype,
***p= 0.0004, One-way ANOVA with Tukey’s multiple comparisons test (f–g) Peritoneal macrophages obtained from individual mice were seeded at 1 ×
105 cells/well and stimulated with LPS (100 ng/ml) for 24 h prior to analysis of metabolites succinate and lactate produced in WT and STAT3 SA cultured
supernatants. Data presented as mean values of duplicate technical replicates ± SEM of five individual mice per genotype, f *p= 0.0292, ***p < 0.0001
g ***p= 0.0004, One-way ANOVA with Tukey’s multiple comparisons test.
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bacteria (Thermo Fisher Scientific, Cat# EC0114) as described previously20. Briefly,
TRAF6 transformed BL21 bacteria were cultured in Luria Broth supplemented with
ampicillin (100 μg/ml) and when an OD600 of 0.6 reached TRAF6 expression was
initiated by incubation with 500 μM Isopropyl β- d-1-thiogalactopyranoside for
16 h at 16 °C. Bacteria was pelleted by centrifugation and lysed by incubation in
50 mM Tris, 150 mM NaCl at pH 7.6 with complete protease inhibitors (Roche)
(10 ml per g of bacteria) and sonicated at 4 °C for 30 s bursts with 30 s between for
a total of 10 cycles. Bacterial lysate was clarified by centrifugation at 40,000 × g for
45 min at 4 °C and the clarified protein bound to glutathione agarose beads
(Thermo Fisher Scientific, Cat# 25236) at 4 °C for 4 h with rotation. Beads were
washed in 10x bead volume of lysis buffer three times. Protein induction and
TRAF6-bound beads were assessed by SDS-PAGE and Coomassie blue staining of
a protein of ~63 kDa. To observe STAT3 binding to recombinant TRAF6, 20 μl of
GST-TRAF6 beads were added to equivalent, clarified lysate from transfected
293T cells described above. Binding was performed at 4 °C for 4 h with rotation.
Beads were washed in 10x bead volume of buffer 50 mM Tris, pH 7.4, 1.0% Triton
X-100, 150 mM NaCl, 1 mM EDTA, 2 mM Na3VO4, 10 mM NaF, 1 mM PMSF
(all Sigma Aldrich) and protease cocktail inhibitor protease (Roche, Cat#
05892970001)) three times for 5 min each with rotation. After the final wash
supernatant was removed and beads resuspended in Laemmli buffer, boiled for
5 min and, together with input protein sample separated by SDS-PAGE. Gels were
transferred to nitrocellulose, blocked in odyssey blocking buffer (Li-cor,
Cat#927–70001) and incubated with indicated primary antibodies. Equivalent
GST-TRAF6 loading was detected by Coomassie blue staining of SDS-PAGE gels
following transfer.
Immunoblot. To detect the phosphorylation status of STAT3, BMDMs (1 × 106)
cells were seeded in 6-well plates 24 h prior to stimulation with agonists (IFNα,
1000U; kind gift Prof Paul Hertzog, Hudson Institute of Medical Research,
Pam3Cys, 100 ng/ml; EMC microcollections, Cat#L2000S), poly I:C, 10 μg/ml;
Invivogen, Cat# tlt-picw, LPS, 100 ng/ml; Invivogen Cat# tlrl-b5lps, Loxoribine,
500 μM, Invivogen, Cat# TLRl-lox and CpG-DNA 1668S, 500 nM, custom synth-
esis Geneworks) for indicated times. pBMDMs were lysed in a modified RIPA lysis
buffer [50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% (v/v) Triton X-100,
0.3% (w/v) sodium deoxycholate, 0.3% (w/v) SDS (all Sigma Aldrich) supple-
mented with protease (Roche, Cat# 05892970001) and phosphatase (Roche, Cat#
04906845001) inhibitors. Protein concentration was assayed using the DC Protein
Assay (Bio-Rad, Cat# 5000111). Samples were reduced and boiled in Laemmli
buffer containing 10% (v/v) beta-mercaptoethanol, resolved by SDS-PAGE,
transferred onto PVDF (EMD Millipore, Cat# IPFL00010), blocked in Odyssey
Blocking Buffer (Li-cor, Cat#927-70001)and incubated with the following primary
antibodies overnight: pY705-STAT3 (1:1000, Cat# 9131), pS727-STAT3 (1:1000,
Cat# 9134), STAT3 (124H6; 1:1000, Cat# 9139), α-TBK-1 (1:1000, Cat# 3013), α-
TBK-1 pSer172 (D52C2; 1:1000, Cat# 5483) were sourced from Cell Signaling
Technology. TRAF6 antibody was from Santa Cruz Biotechnology (d-10; 1:500,
Cat# SC-8409) Membranes were then probed with the appropriate IRDye con-
jugated secondary antibodies: anti-rabbit IgG (1:5000, Thermo Fisher Scientific,
Cat#A21076), anti-mouse IgG (1:5000, Rockland Immunochemicals, Cat#610-445-
002), anti-rat IgG (1:5000, Rockland Immunochemicals, Cat# 612-145-002).
Membranes were scanned using an Odyssey® Infra-red Imaging System. To assess
the role of kinases in STAT3 phosphorylation, BMDMs were pretreated with either
1 μM BX-795 (Caymen Chemicals, Cat# 14932) or 1 μM TG10073 (Selleck Che-
micals, Cat#S2870) for 60 min prior to LPS challenge and assayed as described
above. Full figure immunoblots for all figures presented are provided in the Sup-
plementary Information.
Mitochondria isolation. Pure mitochondria were isolated from iBMDM11. 5 × 107 –
1 × 108 iBMDMs were collected by scraping with a rubber policeman, washed twice
and resuspended in 5× the pellet volume of buffer A (20mM HEPES pH 7.6, 220mM
mannitol, 70mM sucrose, 1mM EDTA, 0.5 mM PMSF and 2mg/ml bovine serum
albumin]. Cells were incubated on ice for 15min to facilitate cell swelling before being
subjected to nitrogen cavitation under 200 PSI of pressure for 5min (PARR instru-
ments, Cat# 4639). Cell homogenate were centrifuged at 800 g for 10min at 4 °C and
the mitochondria containing supernatant retained and centrifuged at 10,000 g for
20min at 4 °C. The supernatant representing the crude mitochondrial fraction was
resuspended in 1ml Solution B (20mM HEPES pH 7.6, 220mM mannitol, 70mM
sucrose, 1 mM EDTA, 0.5mM PMSF) and loaded on top of a stepwise Percoll (GE
Healthcare, Cat# 17-0891-01) gradient comprised of 1mL 80% Percoll/balance
solution A, 4.5ml 56% Percoll/balance solution A and 4.5ml 23% Percoll/balance
solution A. Gradients were centrifuged at 65,000 g for 45min and mitochondria
isolated from the junction of the 56% and 23% layers. Mitochondria were washed
twice in solution B and mitochondrial protein content detected by adding 1 μl of
mitochondrial suspension to 600 μl of 50mM Tris pH 7.4, 0.1% (w/v) SDS and
measuring the absorbance at 280 and 310 nm. Mitochondrial protein concentration in
mg/ml is given by (A280nm−A310nm)/1.05 × 600.
S100 fractions were prepared by collecting the supernatant after the initial
10,000 g crude mitochondrial isolation centrifugation which was centrifuged at
100,000 g in a Beckman benchtop ultracentrifuge. Protein concentration was
characterised by Bradford assay (Thermo Fisher, Cat# 23236). Equivalent protein
was resolved through SDS-PAGE and protein content and fractionation purity
related by western blot with antibodies against the indicated proteins (α-VDAC
D73D12, 1:1000, Cat# 4661; α-Lamin A/C, 1:1000, Cat#2032; Cell Signaling
Technologies; α-ERK1/2 K-23, 1:1000, Santa Cruz Biotechnology, Cat# SC-94).
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Fig. 5 STAT3 pS727 is required for LPS-induced cytokine expression. a Peritoneal macrophages obtained from three mice per genotype were seeded
at 5 × 105 cells/well in and stimulated with LPS (100 ng/ml) for 24 h prior to analysis IL-1β mRNA expression. Data are presented as mean values ± SEM,
***p < 0.0001, n.s.—not significant, one-way ANOVA, Tukey’s multiple comparisons test. Peritoneal macrophages generated from individual WT and
STAT3 mice (3 mice per genotype) were seeded at 1.5 × 105 in triplicate. Macrophages were stimulated for 4, 12, and 24 h with 100 ng/ml of LPS and
b cell lysates assayed for IL-1β and presented as IL-1β/mg of total protein **p= 0.0011, ***p < 0.0001, and cultured supernatants assayed for c TNF (4 h,
***p= 0.0007; 12 h **p= 0.0015; 24 h ***p= 0.0001), d IL-6 (***p < 0.0001), and e IL-10 (*p= 0.0168, ***p < 0.0001) by ELISA. Data presented are the
mean of triplicate values from three individual mice (n= 3) per genotype per time point, Analyses 2 way ANOVA, Sidak’s multiple comparison tests.
WT and STAT3 SA mice (n= 9 mice per genotype) were intraperitoneally treated with 10mg/kg of LPS for 90min and serum analysed for f IL-1β
(*p= 0.0444), g IL-6 (*p= 0.0313), h MCP-1 (**p= 0.0046), i TNF (p= 0.3994) and j IL-10 (p= 0.8204) protein expression by ELISA or cytometric
bead array. Data are presented as mean values ± SEM, Students unpaired t test, two-tailed.
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Gene expression and cytokine analysis. Total RNA from WT and STAT3 SA
peritoneal macrophages was isolated using the RNAeasy Isolation Kit (Qiagen,
Cat# 74104) and reverse transcribed with random hexamers (Thermo Fisher
Scientific, Cat# N8080127) using Moloney murine leukaemia virus reverse
transcriptase (Promega, Cat# 1701) according to manufacturers’ instructions.
mRNA was quantified with SYBR reagents (Thermo Fisher Scientific, Cat#
A46012) using primer pairs targeting il1b (Forward 5′- CAACCAACAAGTGAT
ATTCTCCATG- 3, Reverse 5′- GATCCACACTCTCCAGCTGCA- 3′), and 18S
(Forward 5′- GTAACCCGTTGAACCCATT- 3′, Reverse 5′- CGAATCGAATCG
GTAGTAGCG- 3′). Relative mRNA expression was analysed using the com-
parative CT method, normalising genes of interest to the 18S housekeeping gene
and fold gene induction calculated relative to expression in control samples.
Quantification of cytokines secreted from peritoneal macrophages and serum,
and peritoneal macrophages cellular lysates were conducted using ELISA kits from
R&D Systems (IL-1β: Cat# DY401, TNF: Cat# DY410, IL-6: Cat# DY406 and IL-10:
Cat# DY417) or Cytokine Bead Array Mouse Inflammation kit (BD Biosciences,
Cat# 552364) according to manufacturers’ instructions.
Monitoring mitochondrial ROS production. iBMDMs (4 × 104/ml) were seeded
in triplicate in black microtest Optilux 96-well plates (BD Falcon) in 1% FCS/
DMEM (Gibco) and L-glutamine (Gibco) media for 4 h and then replaced with
phenol-red free 1% FCS/DMEM (Gibco) and L-glutamine (Gibco) 20 h prior to 30
min pretreatment or not with kinase inhibitors (500 nM). Macrophages were
incubated with a final concentration of 1 μM MitoSox (Thermo Fischer Scientific,
Cat# M7512) for 10 min before treatment with LPS (100 ng/ml, Invivogen). Plates
were analysed for fluorescence emission as a marker of mtROS production (exci-
tation/emission 510/580 nm) every 60 min for 4 h (ClarioStar Plate Reader, BMG)
and expressed as the fold induction compared with nontreated control
macrophages.
Seahorse assay and metabolite analysis. The ECAR and OCR of WT and STAT3
SA peritoneal macrophages were measured with a Seahorse XF Analyser. To measure
ECAR and OCR in real-time, cells were isolated from mice, seeded at 1 × 105 cells/
well in eight-well miniplate format and allowed to adhere overnight. Cells were
washed twice in media and treated with LPS (100 ng/ml) for 24 h. One hour prior to
reading cells were washed twice with, and then cultured in Seahorse XF base medium
(Agilent Technologies) supplemented with 1mM pyruvate, 2 mM L-glutamine and
10mM glucose in an incubator without CO2. ECAR and OCR were measured under
basal conditions prior to sequential treatment of cells with electron train chain
inhibitors 1 μM oligomycin, 1.5 μM FCCP-cyanide p-tribluromethoxyphenyl-hydra-
zone, and 1 μM antimycin A and rotenone (Seahorse XF Cell Mito Stress Test kit,
Agilent, Cat# 103015–100). In experiments examining real-time induction of ECAR
by LPS, cells were isolated and seeded as described above, however following basal
measurement of ECAR, cells were challenged with LPS (100 ng/ml) and ECAR
measured for 180min. Data represent mean ± SEM of triplicate wells from at least
three independent mice.
Cultured supernatants from LPS-treated WT and STAT3 SA peritoneal
macrophages were also assayed by Succinic Acid Colormetric Assay Kit
(Biovision, Cat# K649) and Lactate-Glo Assay (Promega, Cat# J5021) for
succinate and lactate metabolite concentrations respectively according to
manufacturers’ instructions.
LPS-induced model of sepsis. Sepsis was induced in male and female WT and
STAT3 SA mice (aged 6–14 weeks) following i.p. injection with 10 mg/kg in a total
volume of 100 μl of LPS (E. coli 055:B5 ultrapure; Invivogen). Mice were culled
after 90 min and serum collected via cardiac puncture for measurement of serum
cytokines.
Quantification and statistical analysis. Statistical analyses were conducted using
specific statistical tests as indicated in the figure legends using GraphPad
8.01 software for each experiment. Data are represented as the mean ± standard
error of the mean as indicated in the figure legends which includes the biological
and experimental replicates. Significance is depicted with asterisks on graph as
follows: *p < 0.05, **p < 0.01 and ***p < 0.001.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The authors declare that the data supporting the findings in this study are available
within the manuscript and Supplementary Information or from the corresponding
author upon request. Source data are provided with this paper.
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